A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies

NCT00977067 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor activity.

Conditions

Interventions

Sponsor

Genentech, Inc.